Tagged with Medicines for Europe

Belgium Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its Presidency Programme, Belgium has highlighted health as one of its 14 focus areas, with the hope of strengthening the three…

Europe The European Union’s just-released and first essential medicines list is the latest in a series of measures designed to limit the bloc’s reliance on countries outside its borders and avoid drug shortages. As Elisabeth Stampa of generic and biosimilar lobby group Medicines for Europe recently explained to PharmaBoardroom, this is…

Europe The COVID-19 pandemic and subsequent shortages of essential medicines and APIs laid bare Europe’s reliance on suppliers outside its borders. To combat this issue and ensure that Europe is better prepared for future health crises, the Spanish Presidency of the EU is advocating for a focus on ‘strategic autonomy’ up…

Europe As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to make medicines more available and accessible across Europe by reducing regulatory exclusivity, speeding up review processes and reinforcing supply chains…

Greece Speaking shortly after the unveiling of a EUR 55 million investment in a new factory in Keratea as part of a wider EUR 155 million spend up to 2025, ELPEN’s Theodore Tryfon outlines the company’s ambitious expansion and diversification plans; his hopes for the future of essential medicine manufacturing in…

Europe Victor Mendonça, chair of the Generic Market Access Committee at Medicines for Europe, outlines why patient access to medicines is at risk due to intense price pressure and unprecedented inflation and proposes ways to tackle this. The COVID-19 pandemic and the conflict in Ukraine have caused unprecedented challenges for Europe,…

Europe The new president of Medicines for Europe, Elisabeth Stampa, outlines one of the priorities of her mandate: working to adjust the EU pharma policy framework to improve access for patients across Europe.    Regulatory flexibilities implemented during COVID-19 showed that the EU system can require one of highest safety, quality…

Europe In conversation with PharmaBoardroom Christoph Stoller and Adrian Van den Hoven of Medicines for Europe, the association representing the European generics, biosimilar and value-added-medicines industry, highlighted their members’ rapid response to the COVID-19 crisis and why Europe-wide reform is needed to avoid future medicine shortages and strengthen the supply chain.…

Medicines for Europe In the wake of the publication of Medicines for Europe’s Lessons Learned from COVID-19 policy paper, Christoph Stoller & Adrian van den Hoven outline the European generics, biosimilar and value-added-medicines industry’s rapid and comprehensive response to the COVID-19 crisis as well as the potential long-term shifts in European pharmaceutical policy…

Generics Arun Narayan is the Chairman of the Value Added Medicines Sector Group at Medicines for Europe, in addition to serving as Head of Global Portfolio Strategy and Head of European Business Operations at Mylan. Narayan introduces compelling reasons why payers in Europe should consider Value Added Medicines, including cost savings…

Europe Isabell Remus, chair of the Biosimilar Medicines Group at Medicines for Europe outlines the issues that need to be addressed to keep driving biosimilar uptake in Europe.   Since the first treatment was approved in 2006, Europe has been at the vanguard of the biosimilar medicines sector, approving more treatments…

Generics Christoph Stoller, general manager for Austria and Germany at Teva was recently elected president of Medicines for Europe, the continent-wide association for the generics and biosimilars industries. Stoller plans to focus his efforts on improving access to generics and biosimilars in Europe, as well as tackling the damaging issue of…